תבנית:תרופה/דוסיטקסל טבע 20 מ"ג / בקבוקון ו- 80 מ"ג/בקבוקון - Docetaxel teva 20 mg/vial and 80 mg/vial: הבדלים בין גרסאות

Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Doxorubicin and cyclophosphamide followed by Docetaxel Teva in combination with trastuzumab (AC-TH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer. Docetaxel Teva in combination with trastuzumab, and carboplatin (TCH) is indicated for the adjuvant treatment of patients with HER2 over-expressing, node-positive or high risk node-negative, breast cancer.Non-small cell lung cancerDocetaxel Teva is indicated for the treatment of patients with advanced non-small cell lung carcinoma Ovarian CancerDocetaxel Teva is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapyProstate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Esophageal cancerDocetaxel Teva is also indicated for the treatment of esophageal cancerGastric cancerDocetaxel Teva is also indicated for the treatment of advanced gastric cancer.Head and neck (SCCHN) • Docetaxel Teva as monotherapy is indicated in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen• Docetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.